Biomarkers (BM) France: results of routine EGFR, HER2, KRAS, BRAF, PI3KCA mutations detection and EML4-ALK gene fusion assessment on the first 10,000 non …

…, J Mazieres, P Missy, F Morin, F Nowak, G Zalcman… - 2013 - ascopubs.org
8000 Background: Personalized medicine is now a reality for advanced NSCLC pts on the
basis of routine screening for EGFR mutation and ALK gene fusion assessment. The French …

[HTML][HTML] Lung cancer in never smokers–a review

S Couraud, G Zalcman, B Milleron, F Morin… - European journal of …, 2012 - Elsevier
… Additionally, the spectrum and type of mutation differ according to smoking status: G to T
transversions are more frequently found in ever smokers, whereas G to A transitions and G to C …

Bevacizumab 15mg/kg plus cisplatin-pemetrexed (CP) triplet versus CP doublet in Malignant Pleural Mesothelioma (MPM): Results of the IFCT-GFPC-0701 MAPS …

G Zalcman, J Mazières, J Margery, L Greillier… - 2015 - ascopubs.org
7500 Background: MPM median overall survival (OS) did not exceed 13 months with
pemetrexed-platinum doublet, with virtually no surviving patients at 5 years. Vascular endothelial …

[HTML][HTML] NSCLC immunotherapy efficacy and antibiotic use: a systematic review and meta-analysis

…, J de Gunzburg, A Andremont, G Zalcman… - Journal of Thoracic …, 2020 - Elsevier
… Andremont MD, PhD c , Gérard Zalcman MD, PhD d e , Renaud Buffet MD a , Pierre-Alain
Bandinelli MSc a … Zalcman discussed the results and reviewed critically the manuscript. …

[HTML][HTML] CaMKII isoforms in learning and memory: localization and function

G Zalcman, N Federman, A Romano - Frontiers in molecular …, 2018 - frontiersin.org
Calcium/calmodulin-dependent protein kinase II (CaMKII) is a key protein kinase in neural
plasticity and memory, as have been shown in several studies since the first evidence in long-…

Weekly paclitaxel plus bevacizumab versus docetaxel as second or third-line treatment in advanced non-squamous non-small cell lung cancer (NSCLC): Results from …

…, O Molinier, S Le Moulec, F Barlesi, G Zalcman… - 2016 - ascopubs.org
9005 Background: Adding bevacizumab to weekly paclitaxel (wPB) has shown synergistic
effect and increased activity in various tumor types. The ULTIMATE study evaluated wPB vs. …

[HTML][HTML] Intergroupe francophone de cancérologie thoracique, Société de pneumologie de langue française, and Société d'imagerie thoracique statement paper on …

…, MP Revel, M Wislez, V Westeel, G Zalcman… - Diagnostic and …, 2021 - Elsevier
Following the American National Lung Screening Trial results in 2011 a consortium of
French experts met to edit a statement. Recent results of other randomized trials gave the …

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate …

…, DR Gandara, BP Levy, SG Nair, G Zalcman… - The lancet …, 2015 - thelancet.com
Background Patients with squamous non-small-cell lung cancer that is refractory to multiple
treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 …

[HTML][HTML] Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry

…, RD Schouten, H Wakelee, DR Camidge, G Zalcman… - Annals of …, 2019 - Elsevier
Background Anti-PD1/PD-L1 directed immune checkpoint inhibitors (ICI) are widely used to
treat patients with advanced non-small-cell lung cancer (NSCLC). The activity of ICI across …

Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors

…, E Deutsch, Y Loriot, F Ghiringhelli, G Zalcman… - Science, 2018 - science.org
Immune checkpoint inhibitors (ICIs) targeting the PD-1/PD-L1 axis induce sustained clinical
responses in a sizable minority of cancer patients. We found that primary resistance to ICIs …